Immune to Cancer: The CRI Blog
-
CRI, LRF Team Up to Improve How Doctors Assess Lymphoma Patients Treated with Immunotherapy
LYRIC might provide a better way to gauge immunotherapy responses in lymphoma patients. Clinical trials are essential…
-
Cancer Research Institute Opens Nasdaq Market in Ceremony Celebrating Cancer Immunotherapy
If you watch the stock markets closely, you may have seen our CEO and director of scientific…
-
Cancer Research Institute Wins $1 Million from Revlon for Women’s Cancers
We took first place in the second annual Revlon LOVE IS ON Million Dollar Challenge.
-
CNN Highlights Cancer Immunotherapy Advances, CRI’s Pioneering Role
First-line lung cancer immunotherapy approval results from century-long effort to harness the immune system to fight cancer.
-
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer
Anti-PD-1 checkpoint antibody is the only immunotherapy approved for first-line treatment for lung cancer patients.
-
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer
Anti-PD-L1 atezolizumab is the second PD-1 pathway drug approved for lung cancer this month.
-
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
-
CICON16: The Future of Cancer Immunotherapy
CICON16 ended by focusing on emerging treatments and technologies in cancer immunotherapy.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.